Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 2, 2012, Pages 464-473

  Salvatorelli, Emanuela ^a   Menna, Pierantonio ^a   Surapaneni, Sekhar ^b   Aukerman, Sharon L ^b   Chello, Massimo ^a   Covino, Elvio ^a   Sung, Victoria ^b   Minotti, Giorgio ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMRUBICIN; DOXORUBICIN; EPIRUBICIN; GLYCOPROTEIN P;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DEAMINATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG UPTAKE; EX VIVO STUDY; FEMALE; FRACTIONAL FLOW RESERVE; HUMAN; HUMAN TISSUE; INCUBATION TIME; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLITE; PHASE PARTITIONING; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; DOXORUBICIN; EPIRUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; P-GLYCOPROTEIN; VERAPAMIL;

EID: 84859989879     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.190256     Document Type: Article

References (43)

1. Barrell D, Dimmer E, Huntley RP, Binns D, O'Donovan C, and Apweiler R (2009) The GOA database in 2009: an integrated Gene Ontology Annotation resource. Nucleic Acids Res 37:D396-D403.
2. Danesi R, Fogli S, Gennari A, Conte P, and Del Tacca M (2002) Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 41:431-444. (Pubitemid 34753680)
3. Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C, Conkling P, Spigel DR, Dudek AZ, Shah C, et al. (2010) Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 28:2598-2603.
4. Ewer MS and Benjamin RS (2006) Doxorubicin cardiotoxicity: Clinical aspects, recognition, monitoring, treatment, and prevention, in Cancer and the Heart (Ewer MS and Yeh E, eds) pp 9-32, BC Decker, Hamilton, Ontario, Canada.
5. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727-741.
6. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, and Sawyer DB (2008) Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 26:3777-3784.
7. Gianni L, Viganò L, Locatelli A, Capri G, Giani A, Tarenzi E, and Bonadonna G (1997) Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15:1906-1915. (Pubitemid 27209520)
8. Gille L and Nohl H (1997) Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radic Biol Med 23:775-782. (Pubitemid 27364872)
9. Grasselli G, Viganò L, Capri G, Locatelli A, Tarenzi E, Spreafico C, Bertuzzi A, Giani A, Materazzo C, Cresta S, et al. (2001) Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. J Clin Oncol 19:2222-2231. (Pubitemid 32366976)
10. Ishizumi K, Ohashi N, and Tanno N (1987) Stereospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds. J Org Chem 52:4477-4485. (Pubitemid 18061289)
11. Kalabus JL, Sanborn CC, Jamil RG, Cheng Q, and Blanco JG (2010) Expression of the anthracycline-metabolizing enzyme carbonyl reductase 1 in hearts from donors with Down syndrome. Drug Metab Dispos 38:2096-2099.
12. Kuhlmann J, Woodcock B, Wilke J, Welling H, and Rietbrock N (1985) Verapamil plasma concentrations during treatment with cytostatic drugs. J Cardiovasc Pharmacol 7:1003-1006. (Pubitemid 15235170)
13. Matsunaga Y, Hamada A, Okamoto I, Sasaki J, Moriyama E, Kishi H, Matsumoto M, Hira A, Watanabe H, and Saito H (2006) Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients. Ther Drug Monit 28:76-82. (Pubitemid 44391698)
14. Meissner K, Sperker B, Karsten C, Meyer Zu Schwabedissen H, Seeland U, Böhm M, Bien S, Dazert P, Kunert-Keil C, Vogelgesang S, et al. (2002) Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. J Histochem Cytochem 50:1351-1356. (Pubitemid 35191479)
15. Menna P, Gonzalez Paz O, Chello M, Covino E, Salvatorelli E, and Minotti G (2012) Anthracycline cardiotoxicity. Expert Opin Drug Saf 11:S21-S36.
16. Menna P, Salvatorelli E, and Minotti G (2008) Cardiotoxicity of antitumor drugs. Chem Res Toxicol 21:978-989.
17. Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229. (Pubitemid 38720829)
18. Monti E, Cova D, Guido E, Morelli R, and Oliva C (1996) Protective effect of the nitroxide tempol against the cardiotoxicity of adriamycin. Free Radic Biol Med 21:463-470. (Pubitemid 26313942)
19. Morisada S, Yanagi Y, Kashiwazaki Y, and Fukui M (1989a) Toxicological aspects of a novel 9-aminoanthracycline, SM-5887. Jpn J Cancer Res 80:77-82. (Pubitemid 20027202)
20. Morisada S, Yanagi Y, Noguchi T, Kashiwazaki Y, and Fukui M (1989b) Antitumor activities of a novel 9-aminoanthracycleine (SM-5887) against mouse experimental tumor and human tumor xenografts. Jpn J Cancer Res 80:69-76. (Pubitemid 20027201)
21. Mross K, Hamm K, and Hossfeld DK (1993) Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. Cancer Chemother Pharmacol 31:369-375. (Pubitemid 23045649)
22. Mushlin PS, Cusack BJ, Boucek RJ Jr, Andrejuk T, Li X, and Olson RD (1993) Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function. Br J Pharmacol 110:975-982. (Pubitemid 24005228)
23. Noda T, Watanabe T, Kohda A, Hosokawa S, and Suzuki T (1998) Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs 16:121-128. (Pubitemid 28495213)
24. Olson RD, Mushlin PS, Brenner DE, Fleischer S, Cusack BJ, Chang BK, and Boucek RJ Jr (1988) Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci U S A 85:3585-3589.
25. Ramond A, Sartorius E, Mousseau M, Ribuot C, and Joyeux-Faure M (2008) Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts. Exp Biol Med (Maywood) 233:76-83.
26. Salvatorelli E, Guarnieri S, Menna P, Liberi G, Calafiore AM, Mariggiò MA, Mordente A, Gianni L, and Minotti G (2006) Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition. J Biol Chem 281:10990-11001. (Pubitemid 43855522)
27. Salvatorelli E, Menna P, Gianni L, and Minotti G (2007) Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies. J Pharmacol Exp Ther 320:790-800. (Pubitemid 46147961)
28. Salvatorelli E, Menna P, Gonzalez Paz O, Surapaneni S, Aukerman LA, Chello M, Covino E., Sung V, and Minotti G (2012) Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin. J Pharmacol Exp Ther 341:474-483.
29. Salvatorelli E, Menna P, Lusini M, Covino E, and Minotti G (2009) Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heart. J Pharmacol Exp Ther 329:175-184.
30. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, and Jones A (2010) Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10:337-351.
31. Stoscheck CM (1990) Quantitation of protein. Methods Enzymol 182:50-68.
32. Suzuki T, Minamide S, Iwasaki T, Yamamoto H, and Kanda H (1997) Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. Invest New Drugs 15:219-225. (Pubitemid 27453876)
33. Swain SM, Whaley FS, and Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869-2879. (Pubitemid 36605157)
34. Takara K, Sakaeda T, Yagami T, Kobayashi H, Ohmoto N, Horinouchi M, Nishiguchi K, and Okumura K (2002) Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull 25:771-778. (Pubitemid 40036714)
35. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, and Schlattner U (2006) New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 41:389-405. (Pubitemid 44362995)
36. Vellonen KS, Honkakoski P, and Urtti A (2004) Substrates and inhibitors of efflux proteins interfere with the MTT assay in cells and may lead to underestimation of drug toxicity. Eur J Pharm Sci 23:181-188.
37. Watts TJ (2010) The in vitro hemolytic effect of diltiazem on erythrocytes exposed to varying osmolarity. Toxicol Mech Methods 20:435-439.
38. Watts TJ and Handy RD (2007) The haemolytic effect of verapamil on erythrocytes exposed to varying osmolarity. Toxicol In Vitro 21:835-839. (Pubitemid 46603242)
39. Whitaker G, Lillquist A, Pasas SA, O'Connor R, Regan F, Lunte CE, and Smyth MR (2008) CE-LIF method for the separation of anthracyclines: application to protein binding analysis in plasma using ultrafiltration. J Sep Sci 31:1828-1833. (Pubitemid 351911746)
40. Wielinga PR, Westerhoff HV, and Lankelma J (2000) The relative importance of passive and P-glycoprotein mediated anthracycline efflux from multidrug-resistant cells. Eur J Biochem 267:649-657. (Pubitemid 30082376)
41. Wojnowski L, Kulle B, Schirmer M, Schlüter G, Schmidt A, Rosenberger A, Vonhof S, Bickeböller H, Toliat MR, Suk EK, et al. (2005) NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112:3754-3762. (Pubitemid 43739516)
42. Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, and Yanagi Y (1998) Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 89:1067-1073. (Pubitemid 28544784)
43. Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, and Yanagi Y (1999) Uptake and intracellular distribution of amrubicin, a novel 9-amino- anthracycline, and its active metabolite amrubicinol in P388 murine leukemia cells. Jpn J Cancer Res 90:685-690. (Pubitemid 29332929)